Oraya Therapeutics

An Exciting New Treatment Option

Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.

Upcoming Events

15th EURETINA Congress
September 16-19 | Nice, France

2015 Annual German Ophthalmology Meeting (DOG)
October 1-4 | Berlin, Germany

Latest Press Releases

Tuesday, June 16, 2015 | Oraya Therapeutics Inc. and Bridge Design announced today that the Oraya IRay® Radiotherapy System has won the Silver award in the radiological and electromechanical devices category of the 18th Annual Medical Design Excellence Awards (MDEA). More >

Tuesday, May 19, 2015 | Oraya Therapeutics Inc. announced today at the Royal College of Ophthalmologists Annual Congress that U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country. Sheffield Teaching Hospitals NHS Foundation Trust alone has treated more than 150 patients in the year since the service was commissioned, with other National Health Service and private centers in England also increasing their treatment with Oraya Therapy. More >

Tuesday, March 3, 2015 | Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. This new indication of use expands upon Oraya’s prior approval for the treatment of wet Age Related Macular Degeneration (AMD) and may offer patients in the United Kingdom, Germany and Switzerland a new treatment option for a vision-threatening condition. More >

Thursday, January 22, 2015 | The AMD Alliance International today led an event at the House of Commons that addressed the current issues the NHS is facing with diagnosing, treating and managing the growing number of ageing people affected by age – related macular degeneration (AMD), the leading cause of blindness in the western world. The event was hosted by Sir David Amess, Member of Parliament for Southend West and sponsored by Oraya Therapeutics, Inc. More >

Wednesday, January 7, 2015 | Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. (Oraya) jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years…More >

Saturday, September 13, 2014 | Oraya Therapeutics Inc. announced today that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. Oraya Therapy uses low-energy, highly targeted X-rays to treat Wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections into the eye. More >

Wednesday, August 20, 2014 | Sheffield Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering appropriate patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD)…More >

Tuesday, August 5, 2014 | Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD)…More >

Tuesday, July 22, 2014 | Oraya® Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany…More >

Latest News

January 23, 2015 | Eyewire Today
The UK’s Leading Blindness Organizations Come Together at House of Commons to Call for Better Funding, Screening, and Treatment for Macular Degeneration.

October 6, 2014 | Mail Online: Health
Painless X-ray that can save failing eyes in 15 minutes.

October 1, 2014 | Fierce Medical Devices
Oraya Therapetics Named Among Fierce Medical Devices 2014 Fierce 15.

September 21, 2014 | Retinal Physician eUpdate
INTREPID Study of Oraya Therapy Continues to Show Favorable Safety Profile.

September 14, 2014 | Eyewire Today
Three-Year Data from Oraya Therapeutics’ INTREPID Study Continue to Show Favorable Safety Profile of Non-Invasive Wet AMD Therapy.

May 29, 2014 | San Francisco Business Times
Oraya Therapeutics named to San Francisco Business Times I-List — the 40-most innovative life science companies in the Bay Area.

Back To Top

The INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization
in AMD
- Peter K. Kaiser, M.D.
© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.